The inkredible race
3D Bioprinting and Automation
The manufacturing of 3-dimensional tissues and organs will require the production of 3-dimensional scaffolding. These bioscaffolds can be produced through a variety of methods including decellularization, electron spinning, and 3D Bioprinting.
3D bioprinters enable customizable structures, like bioscaffolds, to be manufactured quickly and with less variability than if made by hand. In this activity participants will race against a 3D bioprinter to examine how machines help ensure efficient and accurate production of 3D structures.
Examples of Companies, Non-Profit Organizations and Academic and Training Institutions Investigating 3D Bioprinting and Automation in Tissue Engineering
The bioprinting field is growing, enabling new and exciting applications every day. CELLINK focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. Today, CELLINK’s collaborators conduct innovative research that is changing the future of medicine.
The University of Minnesota’s Bioprinting Facility studies human cell viability, proliferation, migration, and differentiation, as well as tissue morphogenesis, in three-dimensionally printed tissue constructs. The center synthesize synthetic and natural biomaterials for use as “inks” in bioprinting projects, and employ a variety of bioprinting techniques and hydrogel crosslinking methods. The facility provides bioprinters, reagents, consumables, an automatic imaging system, and custom support parts to meet all your bioprinting research needs.
The Bioprinting Facility is offering a program to any veterans who are interested in the bioprinting research field. The program consists of two free hands-on sessions (flexible scheduling) and will expose veterans to the fields of tissue engineering and bioprinting.
Some of the biggest impacts 3D printing will have on the world are still quite far away. In labs around the world, people are taking the initial baby steps in bioprinting, tissue printing, using 3D printing in regenerative medicine and making things such as drug loaded implants. While researchers see 3D printed organs in a clinical setting to be something like twenty years out most regular consumers see it a something that is bound to happen in a few years. In the middle of this exciting development sits the Advanced Solutions Life Sciences which makes bioprinters, bioprinting software and bioinks and is a part of the larger firm. Advanced Solutions Life Sciences (ASLS) exists to democratize and continually improve its BioAssembly 3D Bioprinting Platform, resulting in curative therapies that deliver improved longevity and quality of health while reducing global healthcare costs.
FluidForm is building the foundation for the future of Additive Manufacturing, starting with 3D Bioprinting and Regenerative Medicine. They are working to dramatically expand the number and types of materials that can be 3D printed, and build the foundation for the future of additive manufacturing, starting with 3D bioprinting and Regenerative Medicine
Prellis Biologics, Inc. uses a non-toxic, laser-based printing technology decouples speed from resolution, yielding not only the fastest micro-encapsulation technology in the world, but a path to produce functional human tissues.
From biologically compatible materials they build vascularized tissue structures and extracellular matrix to grow human tissues and cells. Our proprietary technology, based on 3D laser lithography, overcomes the major roadblocks in human tissue engineering: speed, toxicity, and resolution. With this novel printing process the Prellis team can creates layers of extracellular matrix containing cells, at ultra-fine resolution with near instantaneous print-speeds. 3D holographic printing methods do not require cell-seeding or additional curing steps for the tissue matrix, significantly decreasing the time to tissue creation. With this proprietary technology they are currently printing cell-containing functional organoids and building microvasculature.
At Organovo, they design and create functional human tissues using a proprietary three-dimensional bioprinting technology. Their goal is to build living human tissues that are proven to function like native tissues. With reproducible 3D tissues that accurately represent human biology, they are enabling ground-breaking therapies by creating functional, three-dimensional tissues that can be implanted or delivered into the human body to repair or replace damaged or diseased tissues.
Rockwell Automation works with top biotech, pharma, and device manufacturers to make their facility of the future a reality today. Organizations can embrace the same digitized automation, IIoT connectivity, single-use equipment, and flexibility as their next competitive advantage. Rockwell is a leader in industrial automation, and will use that expertise to help create miracle manufacturing that will provide artificially produced tissues and even whole organs to people with serious injuries or disease.